EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas

Journal of Cellular Physiology

Volumn 228, Issue 4, 2013, Pages 871-878

  Ripamonti, Francesca ^a   Albano, Luisa ^a   Rossini, Anna ^b   Borrelli, Serena ^b   Fabris, Sonia ^b   Mantovani, Roberto ^b   Neri, Antonino ^b   Balsari, Andrea ^b   Magnifico, Alessandra ^a   Tagliabue, Elda ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DELTA NP63 ALPHA PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; MESSENGER RNA; PROTEIN P63; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; TUMOR INITIATING CELL;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR;

EID: 84871671414     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24238     Document Type: Article

References (37)

1. Abhold EL, Kiang A, Rahimy E, Kuo SZ, Wang-Rodriguez J, Lopez JP, Blair KJ, Yu MA, Haas M, Brumund KT, Altuna X, Patel A, Weisman RA, Ongkeko WM. 2012. EGFR kinase promotes acquisition of stem cell-like properties: A potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS ONE 7:e32459.
2. Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. 2012. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. http://dx.doi.org/10.1016/j.oraloncology.2012.06.006.
3. Bamberger C, Schmale H. 2001. Identification and tissue distribution of novel KET/p63 splice variants. FEBS Lett 501:121-126.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760.
5. Barbieri CE, Barton CE, Pietenpol JA. 2003. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 278:51408-51414.
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. 2006. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578.
7. Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP. 2011. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 99:339-343.
8. Chang SS, Califano J. 2008. Current status of biomarkers in head and neck cancer. J Surg Oncol 97:640-643.
9. Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM. 2006. EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116:401-406.
10. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, Ku HH, Chiou SH, Lo WL. 2009. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 385:307-313.
11. Chu WK, Dai PM, Li HL, Chen JK. 2008. Transcriptional activity of the DeltaNp63 promoter is regulated by STAT3. J Biol Chem 283:7328-7337.
12. Danilov AV, Neupane D, Nagaraja AS, Feofanova EV, Humphries LA, DiRenzo J, Korc M. 2011. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS ONE 6:e26815.
13. Dellavalle RP, Egbert TB, Marchbank A, Su LJ, Lee LA, Walsh P. 2001. CUSP/p63 expression in rat and human tissues. J Dermatol Sci 27:82-87.
14. Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A. 2005. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer 42:117-127.
15. Helmke BM, Reisser C, Idzko M, Dyckhoff G, Herold-Mende C. 2004. Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncol 40:28-35.
16. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G, Candi E. 2008. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ 15:1187-1195.
17. Li Y, Zhou Z, Chen C. 2008. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15:1941-1951.
18. Licitra L, Perrone E, Tamborini E, Bertola L, Ghirelli C, Negri M, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, Bossi P, Locati LD, Cantu G, Scaramellini G, Pilotti S, Tagliabue E. 2011. Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol 22:1886-1893.
19. Lo ML, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, Carinci F, Leonardi R, De LA, Lanzafame S, Bufo P, Piattelli A. 2005. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 36:187-194.
20. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Ménard S, Tagliabue E. 2009. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res 15:2010-2021.
21. Masui H, Castro L, Mendelsohn J. 1993. Consumption of EGF by A431 cells: Evidence for receptor recycling. J Cell Biol 120:85-93.
22. Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. 2003. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope 113:936-939.
23. Matsubara R, Kawano S, Kiyosue T, Goto Y, Hirano M, Jinno T, Toyoshima T, Kitamura R, Oobu K, Nakamura S. 2011. Increased DeltaNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. Int J Oncol 39:1391-1399.
24. Mehra R, Cohen RB, Burtness BA. 2008. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6:742-750.
25. Mihatsch J, Toulany M, Bareiss PM, Grimm S, Lengerke C, Kehlbach R, Rodemann HP. 2011. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol 99:300-306.
26. Milas L, Hittelman WN. 2009. Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol 19:96-105.
27. Monroe MM, Anderson EC, Clayburgh DR, Wong MH. 2011. Cancer stem cells in head and neck squamous cell carcinoma. J Oncol 2011:762780.
28. Pellegrini R, Centis F, Martignone S, Mastroianni A, Tagliabue E, Tosi E, Ménard S, Colnaghi MI. 1991. Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. Cancer Immunol Immunother 34:37-42.
29. Quesnelle KM, Boehm AL, Grandis JR. 2007. STAT-mediated EGFR signaling in cancer. J Cell Biochem 102:311-319.
30. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB. 1997. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191-1197.
31. Sen T, Chang X, Sidransky D, Chatterjee A. 2010. Regulation of DeltaNp63alpha by NFkappaBeta. Cell Cycle 9:4841-4847.
32. Senoo M, Pinto F, Crum CP, McKeon F. 2007. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536.
33. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S, Ishioka C. 1999. The transcriptional activities of p53 and its homologue p51/p63: Similarities and differences. Cancer Res 59:2781-2786.
34. Shintani S, Matsuo K, Crohin CC, McBride J, Tsuji T, Donoff RB, Posner M, Todd R, Wong DT. 1999. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. Cancer Res 59:4142-4147.
35. Testoni B, Borrelli S, Tenedini E, Alotto D, Castagnoli C, Piccolo S, Tagliafico E, Ferrari S, Vigano MA, Mantovani R. 2006. Identification of new p63 targets in human keratinocytes. Cell Cycle 5:2805-2811.
36. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. 2003. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 23:2264-2276.
37. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.